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CHAPTER 1
 
INTRODUCTION
 
Amoxicillin [D-(-)-a-amino-p-hydroxybenzyl-penicillin trihydrate], a 
semisynthetic penicillin, was approved for use by the U.S. Food and Drug 
Administration (FDA) in 1974. There is evidence from in vitro research and in vivo 
animal experiments that the efficacy of fl-lactam antibiotics depends mainly on the 
length of time that bacteria are exposed to antibiotic concentrations above the 
minimum inhibitory concentration (MIC). Consequently, a sustained release dosage 
form of 13-lactam antibiotics might be therapeutically more efficacious than the 
existing conventional products, which are rapidly absorbed to produce transient peaks 
in serum drug concentrations. Currently, no commercial sustained release dosage 
forms of amoxicillin are available. 
Several attempts have been made by others to develop a sustained release 
amoxicillin product with little success. Hilton and Deasy (1) reviewed the literature 
relative to efforts to formulate sustained release amoxicillin. They developed a 
product with an excellent in vitro sustained release patten, but the product in vivo was 
only 64.4% bioavailable in comparison with a commercial immediate release product. 
Llabres et al. (2, 3, 4) reported that fat matrix and fat-silica matrix sustained 
release formulations resulted in only 13-50% of the dose excreted in the urine. This 
would be a bioavailability of about 19-74%, by comparison to the commercial 2 
immediate release product. Arancibia et al. (5) reported development of a controlled 
released amoxicillin formulation, but details of the composition of the formulation 
were not provided. The controlled release formulation had rather low bioavailability 
in comparison with the conventional product and both gave no detectable drug 
concentrations in plasma after 8 hours of administration. Delgado Charro and Vila 
Jato (6) tested a formulation containing amoxicillin and Gelucire 64/02. The 
formulation showed adequate sustained release properties in vitro. In vivo, the 
amount of unchanged amoxicillin excreted in the urine decreased progressively as the 
Gelucire 64/02 increased in the formulation. They conclude that there  may be an 
absorption window for this drug. 
The purpose of this research was to develop and evaluate a new oral sustained 
release dosage form of amoxicillin for use in human subjects. Chapter 1 is an 
introduction. Chapter 2 deals with development of sustained release tablets containing 
amoxicillin, and in vitro dissolution studies for the tablets.  Tablets with the desired 
controlled released rate in vitro were developed. Chapter 3 deals with development of 
an HPLC analysis for determination of amoxicillin in urine. The HPLC procedure 
was modified to achieve optimal peak resolution and retention time. The assay 
method was used to evaluate both the sustained release and immediate release dosage 
forms of amoxicillin in human subjects. Results of oral administration of amoxicillin 
suspension in repeated low doses over short time intervals to simulated continuous 
oral input supports the suggestion of an absorption window for amoxicillin. 3 
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CHAPTER 2
 
DEVELOPMENT AND CHARACTERIZATION OF
 
A SUSTAINED RELEASE AMOXICILLIN DOSAGE FORM
 
ABSTRACT 
Amoxicillin trihydrate was mixed with stearic acid to control the released rate 
of amoxicillin. The percentage of stearic acid in the mixture is a key factor in 
controlling release rate of the drug. Dissolution was evaluated using the USP paddle 
method. A sustained release dosage form for amoxicillin was developed containing 
14.5% stearic acid that released nearly 100% of the amoxicillin during an 8 hour 
period. 
A sustained released dosage form of amoxicillin with stearic acid and 
ethylcellulose was also tested. The release rate was too low to release a practical 
amount of drug during a 12 hour period. 5 
INTRODUCTION
 
Amoxicillin [D- ( -) -a- amino- p- hydroxybenzyl- penicillin trihydrate], synthesized 
from 6-aminopenicillanic acid, is an orally absorbed, acid stable (pH 4.8), broad 
spectrum antimicrobial agent. The drug is a member of the aminopenicillin class of 
penicillin derivatives. Aminopenicillins have an amino group (NH2) on the carbon 
atom of the side chain of the penicillin molecule, which enhances activity against 
gram negative bacteria while retaining activity against gram positive bacteria (1). 
Typical of penicillins, the bactericidal activity of amoxicillin is characterized 
by an initial rise in the killing rate with increasing concentrations, but only until 
concentrations reach four to five times the minimum inhibitory concentration (MIC). 
Very high concentrations of (3-lactam antibiotics in serum and tissue do not result in 
more rapid killing of bacteria. Furthermore, as soon as amoxicillin concentrations 
fall below the MIC, most pathogens rapidly recover and start to grow again. Only 
with staphylococci have prolonged in vivo postantibiotic effects been consistently 
observed for fl-lactam antibiotics. Thus, the duration of time that drug concentrations 
in serum and tissue exceed the MIC has been shown to be a pharmacokinetic 
parameter of major importance. The goal of dosing 0-lactams would be to maximize 
the time of microbial exposure to active drug concentrations. According to 
Schumacher's method, the hours above the MIC during a 72 hour period is 71 hours 
for 750 mg amoxicillin, twice a day, zero order input and 62 hours for 500 mg 
amoxicillin, three time a day, first order input (2). Therefore, an effective sustained 
release formulation for amoxicillin would be a most suitable form for this purpose. 6 
Also, reduced frequency of administration is more convenient for patients and may 
thereby improve compliance (3, 4, 5, 6, 7). 
First, the release rate of amoxicillin was modified with a stearic acid and 
ethylcellulose matrix. By varying the percentage of stearic acid and ethylcellulose, 
the desirable release rate could be approached (8). However, results show that 
ethylcellulose has a strong retarding effect on the drug release rate in vitro. A 
formulation using a mixture of drug and stearic acid alone was found to give a desired 
in vitro dissolution curve. 7 
MATERIALS AND METHODS
 
Materials 
Amoxicillin trihydrate USP, compacted, Mfg. lot No. 6453-XS, was kindly 
supplied by Biocraft Laboratories, Inc. 95% stearic acid was purchased from Aldrich 
Chemical Company, Inc. (Milwaukee, WI 53233, USA). Stearic acid USP was 
purchased from J. T. Baker Inc. (Phillipsberg, NJ 08863, USA). Magnesium 
stearate, purified, was purchased from Fisher Scientific Company (Pittsburgh, 15219, 
USA). 95% myristic acid, and 99% stearic acid were purchased from Sigma 
Chemical Company (ST. Louis, MO 63178, USA). Ethylcellulose, viscosity 45,  was 
purchased from The Dow Chemical Company (Midland, MI 48674, USA). 
Formulations 
Formulations consisted of a mixture of amoxicillin trihydrate, ethylcellulose, 
stearic acid, and magnesium stearate. For formulations which did  not contain 
ethylcellulose, all ingredients were passed through a 20 mesh sieve, then mixed 
together and stirred well. For formulations which contain ethylcellulose, stearic acid 
was melted and mixed with a 1% (w/w) ethanol solution of ethylcellulose at 50 ­
60°C, then mixed with amoxicillin and dried at 37°C  over night. The dried material 
was then mixed with magnesium stearate. Tablets were produced by placing an 
appropriate amount of the mixture, containing 750 mg amoxicillin as the trihydrate 8 
form, between two oval concave punches in a 0.750" x 0.378" oval shaped die, and 
compressing with a load of 8000 pounds force on a Carver Laboratory Press (Fred S. 
Inc., Summit, NJ). 
Dissolution tests 
In vitro dissolution of each formulation was performed at least in duplicate 
using the USP dissolution paddle method apparatus (Hanson Research  Corp. 
Northridge, CA) at 50 rpm and 37°C. Each formulation was pretreated with 
simulated gastric fluid without pepsin (pH 1.4 ± 0.1) for 2 hours, then was 
transferred into simulated intestinal fluid without pancreatin (pH 7.4 ± 0.1). 
Dissolution samples were collected at 1, and 2 hours (in gastric fluid), and 3, 4, 6, 8, 
12, and 24 hours (in intestinal fluid) with replacement of equal volume ,  equal 
temperature media. The effect of varying percentages of ethylcellulose and stearic 
acid, the effect of purity of the stearic acid, and the effect of compression pressure 
were studied. All dissolution samples were assayed at 274 nm using an HP 8452A 
Diode Array spectrophotometer (Hewlett-Packard company). The percentage of 
amoxicillin released is the amount of amoxicillin released divided by the amount of 
amoxicillin in the tablet (750mg), multiplied by 100. 9 
Standard curves 
Standard solutions were prepared with concentrations of amoxicillin in a range 
of 0.02  0.5 mg/ml. Then the standard curves for intestinal and gastric fluid were 
saved in the disk.  Calibration the spectrophotometer before each assay. 10 
RESULTS AND DISCUSSION 
Figure 2.1 shows dissolution profiles of amoxicillin in formulations which 
contain different percentages of ethylcellulose. The formulations are summarized in 
Table 2.1. From Figure 2.1 (a) in intestinal fluid only, Figure 2.1 (b) in gastric fluid 
followed by intestinal fluid, it can be seen that release rates decrease with increasing 
percentage of ethylcellulose. The formulation with only 0.16% ethylcellulose gave an 
approximately zero order release over 24 hours when allowed to dissolve in intestinal 
fluid only. 
Table 2.2 summarizes formulations tested which did not contain any 
ethylcellulose. The dissolution profiles of amoxicillin from these formulations 
containing only stearic acid are shown in Figure 2.2 (a) in intestinal fluid only, Figure 
2.2 (b) in gastric fluid followed by intestinal fluid. The release rate decreased with 
increasing percentage of stearic acid in the formulation. 
T50% (time to release 50% of drug) of amoxicillin from the different 
formulations containing different percentages of stearic acid are compared in Figure 
2.3. As the percentage stearic acid increased, the T50% of amoxicillin increased for 
dissolution in intestinal fluid only. The T50% was 3.2,  5.6, and 8.4 hours for 
formulations containing 7.8, 14.5, and 20.2% stearic acid, respectively. However, 
with 2 hours gastric fluid pretreatment, amoxicillin dissolutions were much more 
rapid due to the higher solubility in lower pH value, the T50% was  1.4, 1.5, and 2.2 
hours for formulations containing 7.8, 14.5, and 20.2% stearic acid, respectively. 11 
Table 2.1  Formulations which contain fixed amount of stearic acid and different 
ethylcellulose concentrations 
Ingredients  Formulations" 
#1  #3 
Amoxicillin trihydate (g)  5.74  5.74  5.74 
Magnesium stearate (g)  0.18  0.18  0.18 
Stearic acid (95%, g)  0.50  0.50 0.50
 
Ethylcelluloseb (gam)  1.00  2.50  4.00 
Stearic acid (95%) and ethylcellulose ethanol solution are combined in a beaker, 
stirred at 50-60°C to melt the stearic acid, then amoxicillin is added, and mixed for 10 
min. The product is dried at 37°C over night, mixed with magnesium stearate, and 
tableted. 
Ethylcellulose (viscosity 45) dissolved in ethanol solution (1%, w/w). 12 
0.16% ethylcellulose
 
0.39% ethylcellulose
 
0.62% ethylcellulose
 
4  8  12  16  20 24 
Time (hr) 
Figure 2.1a	  Effect of ethylcellulose on the dissolution profiles of amoxicillin in 
simulated intestinal fluid only. Each data point represents the mean ± 
standard deviation of four replications, except where the standard 
deviation is too small to show. 13 
0.16% ethylcellulose 
't?'  0.39% ethylcellulose 
1r  0.62% ethylcellulose 
4  8  12  16 20 24 
Time (hr) 
Figure 2.1b	  Effect of ethylcellulose on the dissolution profiles of amoxicillin with 2 
hours simulated gastric fluid pretreatment. Each data point represents 
the mean ± standard deviation of two replications, except where the 
standard deviation is too small to show. 14 
Table 2.2  Formulations which contain different amount of stearic acid 
Ingredients  Formulations 
#1  #2 #3 
Amoxicillin trihydate (g)  5.74  5.74  5.74 
Magnesium stearate (g)  0.18  0.18  0.18 
Stearic acid (95%, g)  1.50 (20.2%)  1.00 (14.5%)  0.50 (7.8%) 15 
7.8% stearic acid 
v	  14.5% stearic acid 
20.2% stearic acid 
4  8  12  16 20 24 
Time (hr) 
Figure 2.2a	  Effect of stearic acid on the dissolution profiles of amoxicillin in 
simulated intestinal fluid only.  Each data point represents the mean ± 
standard deviation for four replications, except where the standard 
deviation is too small to show. 16 
fz
V
 
7.8% stearic acid
 
14.5% stearic acid 
20.2% stearic acid 
4  8  12  16 20 24 
Time (hr) 
Figure 2.2b	  Effect of stearic acid on the dissolution profiles of amoxicilrin with 2 
hours simulated gastric fluid pretreatment.  Each data point represents 
the mean ± standard deviation for two replications and six replications 
for formulation containing 14.5% stearic acid, except where the 
standard deviation is too small to show. 17 
intestinal fluid only
 
V'  gastric fluid pretreated
 
V
 
4  8  12  16 20 24
 
Stearic acid %
 
Figure 2.3  Time for 50% amoxicillin dissolved as a function of percentage stearic 
acid. 18 
Dissolution of a sustained release tablet containing  14.5% stearic acid 
compared with conventional immediate release capsules in 2 hours gastric fluid 
followed by intestinal fluid is shown in Figure 2.4.  The sustained release formulation 
gives a slower release patten with release being nearly complete at 8 hours. 
The purity of stearic acid is a factor which may change the release rate of 
drug. Formulations containing 95% stearic acid mixed with 95%  myristic acid are 
summarized in Table 2.3.  The dissolution profiles for amoxicillin from these 
formulations are shown in Figure 2.5 (a) in intestinal fluid only and Figure 2.5 (b) in 
gastric fluid followed by intestinal fluid. Figure 2.5 shows that the formulation which 
contains equal proportions of stearic acid and myristic acid gave the fastest release 
rate. There is little difference in the dissolution profiles among those formulations 
which contain 50/50, 80/20 stearic acid and myristic acid, 100% stearic acid, and 
stearic acid USP. These results suggest that small differences in stearic acid purity 
will not dramatically affect amoxicillin dissolution. 
Figure 2.6 shows that compression pressure had an effect on amoxicillin 
dissolution. As tableting pressure increases, dissolution decreases. A compression 
load of 8,000 pounds force was chosen for the tablets in this study. 19 
SR (14.5% stearic acid) 
v  IR capsules 
4  8  12  16 20 24 
Time (hr) 
Figure 2.4	  Comparison of a sustained release (SR) tablet with commercially 
available immediate release (IR) capsules. Dissolution profiles of 
amoxicillin with 2 hours simulated gastric fluid pretreatment. Each 
data point represents the mean ± standard deviation, two replications 
for IR and six replications for SR, except where the standard deviation 
is too small to show. 20 
Table 2.3  Formulations which contain stearic acid of differing purities 
Ingredients  Formulations 
#1  #2  #3 #4 
Amoxicillin trihydate (g)  5.74  5.74  5.74  5.74 
Magnesium stearate (g)  0.18  0.18  0.18  0.18 
Stearic acid (g)  1.00  1.00  1.00  1.00 
Ratio' (w/w)  1006  80b:20c  50b:50`  100d 
Melting point  67-69°C  61.5-62.5°C  49-51°C  54°C 
Ratio of stearic acid and myristic acid. Weigh 95% stearic acid and 95% myristic 
acid (w/w), mix together, heat until melted, cool to room temperature, powder, and 
pass through a 20 mesh sieve. 
95% stearic acid. 
95% myristic acid. 
d USP stearic acid (mixture of stearic acid and palmitic acid). 21 
SA 
o SA/MA=80/20 
y SA/MA=50/50 
USP SA 
0  4  8  12  16  20  24 
Time (hr) 
Figure 2.5a	  Effect of the purity of 95% stearic acid (SA) mixed with 95% myristic 
acid (MA) on dissolution profiles of amoxicillin in simulated intestinal 
fluid only. Each data point represents the mean ± standard deviation 
for two replications, expect where the standard deviation is too small to 
show. 22 
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40 
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24 
Figure 2.5b	  Effect of the purity of 95% stearic acid (SA) mixed with 95% myristic 
acid (MA) on dissolution profiles of amoxicillin with 2 hours simulated 
gastric fluid pretreatment. Each data point represents the mean ± 
standard deviation for two replications, except where the standard 
deviation is too small to show. 23 
6000 pounds force
v 8000 pounds force 
V  10000 pounds force 
4  8  12  16 20 24 
Time (hr) 
Figure 2.6	  Effect of compression pressure on drug mixture containing 14.5% USP 
stearic acid. Dissolution profiles of amoxicillin in simulated intestinal 
fluid only. Each data point represents the mean ± standard deviation 
for two replications, except where the standard deviation is too small to 
show. 24 
CONCLUSION 
The release rates for drug compressed into tablets are affected by many 
parameters. The percentage of stearic acid in a tablet formulation is a key factor for 
controlling the release of amoxicillin in the sustained release dosage forms tested. Of 
the several formulations tested which contain different percentages of stearic acid, the 
best formulation contained 14.5% stearic acid and gave the desired controlled release 
over a 8 hour period in vitro. 
The purity of the stearic acid had some effects on drug release, but a small 
impurity will not dramatically affect amoxicillin dissolution. Tableting pressure also 
had some effects on amoxicillin dissolution. As tableting pressure increased, the rate 
of dissolution decreased. 25 
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CHAPTER 3
 
DETERMINATION OF AMOXICILLIN IN URINE
 
BY HPLC AND EVALUATION OF SUSTAINED RELEASE
 
AMOXICILLIN IN HUMAN SUBJECT
 
ABSTRACT 
The stability of amoxicillin in urine was studied. After pH adjustment, 
amoxicillin was sufficiently stable in urine for up to 24 hours to determine drug 
concentrations with an HPLC autoinjector. 
An HPLC analytical procedure for determination of amoxicillin concentrations 
in human urine using reversed-phase column (C18, 5 Am), with UV detection at 229 
nm, is described. Optimal elution conditions were determined by studying several 
variables: pH, buffer concentration, and ratio of mobile phase components. A 
mobile phase consisting of 5% (v/v) methanol in 0.005 M potassium dihydrogen 
phosphate buffer (pH = 4.80 ± 0.05) at a flow rate of 1.2 ml/min provided good 
resolution of amoxicillin and 4-acetamidophenol (APAP, internal standard) peaks with 
a retention time of less than 24 minutes. The method is simple, rapid, and reliable. 
Immediate release amoxicillin capsules, suspension, and sustained release 
amoxicillin tablets were evaluated in one human subject. There were two sustained 
release tablets, SR(A) and SR(B), containing 7.8 and 14.5% stearic acid, respectively. 
The desired sustained release patten was not shown in vivo even though these SR 
formulations showed sustained release in vitro. A relative bioavailability from these 
formulations of 30 40% was found, when compared to the immediate release 27 
capsules. Results of oral administration of amoxicillin suspension in repeated small 
doses at frequent times to mimic sustained release input support the presence of an 
absorption window for amoxicillin. 28 
INTRODUCTION 
Quantification of antibiotics were originally performed using microbiological 
techniques. This guarantees determination of the microbiologically active principles, 
including active metabolites. Disadvantages of such techniques are non-selectivity 
(i.e. active metabolites are co-determined), relatively long analysis times, and low 
precision of the results. The relative standard deviation is generally about 15% (1, 
2). Recently, many chemical assays based on HPLC methods have been introduced 
offering rapid, selective, and precise methods of determination for this class of 
compounds (3, 4, 5, 6, 7, 8, 9, 10). All these methods have particular 
merits and demerits in respect to sensitivity, selectivity, specificity, and convenience. 
High drug concentrations in urine are possible with low blood concentrations 
because the volume of urine is much less than the total body volume of distribution. 
Therefore, the sensitivity of the HPLC assay method was not a great concern for this 
study. The purpose of this study was to develop a simple and rapid technique for the 
determination of amoxicillin in urine to evaluate the relative bioavailability of the 
sustained release amoxicillin formulations. 
Immediate release capsules, suspension and sustained release amoxicillin 
SR(A) and SR(B) were given to a single human subject. The desired sustained 
release patten was not found. The relative bioavailabilities of the sustained release 
formulations were quite low, only 30 - 40% compared to a commercially available 
immediate release capsule. 29 
MATERIALS AND METHODS 
Materials 
Amoxicillin capsules (Novopharm Inc., Schaumburg, IL 60173 USA) and 
amoxicillin suspension (Warner Chicott labs, Morris plains, NJ 07950 USA) were 
purchased from The Oregon State University Student Healthy Center pharmacy. 
Amoxicillin trihydrate USP, compacted, Mfg. lot No. 6453-XS, was kindly supplied 
by Biocraft Laboratories, Inc. Potassium dihydrogen phosphate, disodium hydrogen 
phosphate, citric acid, and HPLC grade methanol were purchased from Mallinckrodt 
Specialty Chemicals Company (Paris, Kentucky 40361, USA). Perchloric acid 
(concentrated) was purchased from I. T. Baker Chemical Company (Phillipsburg, NJ 
08865, USA). 4-Acetamidophenol (APAP) was purchased from Sigma Chemical 
Company (ST. Louis, MO 63178, USA). HPLC columns (C18, particle size 5 tn, 
pore size 100 A) were purchased from Rainin Instrument Co., Inc. (Woburn, MA 
01801, USA) 
The solution for protein precipitation was 0.33 N perchloric acid solution. 
The pH of the solution was below 2. The solution for internal standard was 1 mg/ml 
APAP stored refrigerated in foil-covered glass to exclude light. The solution for pH 
adjustments was 100 ml of 0.5 M disodium hydrogen phosphate and 350 ml of 
deionized water adjusted with 1 M citric acid to pH 4.85 before addition of water to 
500 ml. The mobile phase was 5% methanol in 0.005 M potassium dihydrogen 30 
phosphate buffer (pH = 4.80 ± 0.05). Before use, the mobile phase was degassed 
20 minutes by stirring under vacuum. 
Apparatus 
The HPLC system consisted of a Waters Associates (Milford, MA, USA) a 
model 6000A solvent delivery system, a WISP 712 autoinjector, and a model 441 UV 
absorbance detector. A 4.6 x 250.0 mm C18 column with a guard column 
(Microsorb-MV, 5 pm, 100 A, Rainin Instrument Co., Inc., Mack Road, Woburn, 
MA 01801, USA) were used to separate the analytes. Data were recorded on a strip 
chart recorder (Linear Instruments Corp., Irvine, CA). 
Sample preparation 
Method by Vree, et al. (1): 20 Al urine and 30 Al 4-Acetamidophenol (APAP) 
(1 mg/m1) were mixed with 0.5 ml of perchloric acid (0.33 N) on a Vortex mixer. 
100 Al were injected onto the high performance liquid chromatograph. 
Method by Carlqvist and Westerlund (2): 20 /21 urine and 30 Al APAP (1 
mg/ml) were mixed with 0.5 ml of pH adjustment solution (pH 4.85) on a Vortex 
mixer. 100 id were injected onto the high performance liquid chromatograph. 31 
Standard curve 
Standard solutions in urine were prepared with amoxicillin concentrations in a 
range of 0.2 to 2.0 mg/ml. Due to the instability of the amoxicillin in urine, the 
standard solutions had to be prepared fresh daily before assay. A standard calibration 
curve was constructed by plotting the ratio of amoxicillin peak height to internal 
standard peak height versus known amoxicillin concentration. There were no 
detectable peaks from vehicles or solvents. 
In vivo study protocol 
One human subject (32 years old female, healthy, and free of any medications) 
participated in the study. Subject fasted at least 12 hours before taking the drug. For 
each trial, the subject had at least a one day wash-out period. The half life of 
amoxicillin is relatively short, 1.05 hr (11), and the data show no accumulation 
from the sustained release products. 750 mg of amoxicillin were administered with 
each dose. The full volume of urine produced during the study period was collected 
and measured for all time points except time 0, which was used as a blank for 
analysis. A small portion of each urine sample was prepared as described and 
analyzed for amoxicillin concentration by HPLC with UV detector at 229  nm. Urine 
samples were collected at 0, 1, 2, 3, 4, 5, 6, 8, and 12 hours. 32 
RESULTS AND DISCUSSION 
Stability study 
Amoxicillin is an amphoteric compound. The pIC, values of the COOH, NH2, 
and OH groups are 2.4, 7.4, and 9.6, respectively; thus the drug has a slightly acid 
character. A 0.2% (m/v) solution of the drug in CO2 free water has a pH of 3.5 ­
5.5. Owing to its strongly polar character, amoxicillin is relatively soluble in water. 
The solubility at pH 4 - 8 varies from 4.2 g/1 to 9.0 g/l. Amoxicillin is unstable in 
the strongly acid solutions required for the drug to be present in the unionized form 
(pH below 2.4) (12). 
Amoxicillin is rather unstable in biological fluids (2). A urine sample 
containing 20.0 mg/ml lose 53.6% of drug at 37°C during a 24 hour period (Figure 
3.1). Higher concentrations of drug in urine seemed to be more unstable than lower 
concentration. The reason is probably due to the tendency of aminopenicillins to 
polymerize at high concentrations (13). Studies of the stability of the drug in urine 
at physiological and ambient temperatures indicated the importance of rapid handling 
of specimens (2). For this experiment, all samples were pH adjusted within 30 
minutes and analyzed within 8 hours after sample collection. 
The method by Vree, et al. (1) is very simple and rapid.  It is very useful for 
an immediate assay after a single sample is collected. The suitability of the method 
for the assay of large numbers of samples is limited since amoxicillin degrades over 33 
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Figure 3.1	  Stability of amoxicillin in urine at 37°C. Aliquot of the sample were 
taken from a thermostatted water bath and immediately frozen by a 
dry ice-ethanol mixture and stored at -70°C before analysis by 
HPLC (2). 34 
time. Figure 3.2 shows that the peak height ratio of amoxicillin and APAP in urine 
decreased over a 20 hour period, due to amoxicillin degradation. 
Thus, the Carlqvist and Westerlund method (2), which adjusts the pH of urine 
samples to overcome the instability of amoxicillin in body fluids, was used. 
Amphoteric penicillins often have their optimal stability at the isoelectric point. For 
amoxicillin, the isoelectric point is pH 4.8. The addition of 0.5 ml pH adjustment 
solution to 20 µl of urine provided conditions that kept amoxicillin intact for at least 
24 hours at room temperature. This is an adequate time to perform the assays with 
an automated injector. Figure 3.3 shows the peak height ratios of amoxicillin and 
APAP in urine over a 48 hour period. The urine samples were stable up to 24 hours. 
HPLC analysis 
The volume ratio of methanol in potassium dihydrogen phosphate buffer had a 
significant effect on the retention time of amoxicillin (see Table 3.1). The higher the 
percentage of methanol, the shorter the retention time of the amoxicillin. Excellent 
resolution and retention times were obtained with 5% (v/v) methanol in 0.005 M 
potassium dihydrogen phosphate buffer (pH = 4.80 ± 0.05). 
The analysis and recording parameters as shown in Table 3.2 provided 
excellent conditions for measurement of amoxicillin and APAP peak heights. Under 
the conditions described, amoxicillin and internal standard were clearly separated and 
eluted within 24 minutes. Mean retention times for amoxicillin and APAP were 6.5, 35 
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Figure 3.2	  Stability of amoxicillin at room temperature during a 20 hour period. 
Samples were prepared by the method of Vree, et al. (1). 36 
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Figure 3.3  Stability of amoxicillin at room temperature during a 48 hour period. 
Samples were prepared by the method of Carlqvist and Westerlund (2). 37 
Table 3.1	  Effect of volume ratio of methanol in potassium dihydrogen phosphate 
buffer on the retention time of amoxicillin and APAP 
Volume ratio*	  Retention time (minutes) 
Amoxicillinb	  APAPa 
100: 400  3.29	  NAd 
75 : 425  3.76	  NA 
50 : 450  4.74	  NA 
25 : 475  6.50	  19.79 
a Volume ratio of methanol and 0.005 M KH2PO4 buffer. 
b 0.04 mg/ml amoxicillin aqueous solution. 
1 mg/ml APAP aqueous solution. 
d Not measured. 
Table 3.2	  Optimal parameters for HPLC analysis with UV detector 
Mobile phase = 5% methanol in 0.005 M KH2PO4 buffer 
Flow rate = 1.2 ml / min 
Wavelength = 229 nm 
Sensitivity = 0.5 AUFS 
Chart speed = 10 cm / hr 38 
and 19.8 minutes, respectively. Figure 3.4 shows an average standard curve for 
amoxicillin from nine standard curves produced over a four month period. Slope, 
intercept, and correlation coefficient were 0.81309, -0.0104, and 0.999, respectively. 
In vivo study 
Amoxicillin is excreted 50 70% unchanged in the urine. Most of the drug is 
excreted within 2 hours of dosing, but effective concentrations against susceptible 
organisms remain in the urine up to 8 hours after administration (14). 
Figure 3.5 shows the cumulative amount of drug excreted in urine versus time. 
Figure 3.6 shows the urinary excretion rate of amoxicillin with time. The final 
percentages of drug recovered from urine were 63.3, 19.0, and 25.2% for immediate 
release capsules, SR(A), and SR(B), respectively. The relative bioavailability for the 
sustained release formulations were rather low, only 30 40% compare to immediate 
release capsules. These results are consistent with other studies (15, 16, 17, 
18, 19, 20, 21). 
There are a number of investigations into the absorption process of 
aminopenicillins (22, 23, 24, 25). The absorption mechanisms of amino 13­
lactam antibiotics are complicated and there is controversy about the extent to which 
carrier-mediated transport systems participate in the absorption process. Absorption 
has been proposed to occur mainly in the upper small intestine, which is consistent 39 
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Figure 3.4	  An average standard calibration curve for amoxicillin concentration 
(0.2 to 2.0 mg /m1) versus peak height ratio of amoxicillin to APAP 
(internal standard). 40 
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Figure 3.5	  Comparison of amoxicillin excreted in urine from capsules, SR(A), and 
SR(B). Each data point represent the mean ± standard deviation for 
two trials, except where the standard deviation is too small to show. 41 
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Figure 3.6	  Comparison of urinary excretion rates of amoxicillin from capsules, 
SR(A), and SR(B). Each data point represent the mean ± standard 
deviation for two trials, except where the standard deviation is too 
small to show. 42 
with the results reported herein. Thus, absorption would occur only in a narrow 
zone, an absorption window. 
If this is true, an obvious way to design oral formulations for optimal 
bioavailability is to maximize the release rate of amoxicillin from solid dosage forms 
in the upper small intestine. The best way to provide amoxicillin would be as an 
already dissolved form. Hespe, et al. (21) compared an effervescent tablet and a 
commercial reference formulation. The effervescent tablet performs best by showing 
the highest AUC and C., values. 
One approach to evaluate oral sustained release input is to calculate the amount 
of drug released every hour in vitro for the sustained release formulation during an 8 
hour period of dissolution. The subject may then take the same amount of drug in 
suspension form at the same rate to minimize the formulation effect. The resulting 
excretion profile from this method should correlate closely to the desired excretion 
profile for sustained release oral input. Table 3.3 shows the amount of amoxicillin 
released from a sustained release tablet in vitro. Figure 3.7 shows that the excretion 
profile for the desired sustained release by intermittently dosed suspension is much 
higher than that of the observed sustained release formulation. The decreased 
excretion might be due to an absorption window. No absorption occurred after the 
sustained release tablet had passed the absorption window. 
Figure 3.8 and Figure 3.9 indicate that bioavailabilities for an equal dose of 
amoxicillin in commercially available capsules, commercially available suspension, 43 
Table 3.3  Amount of amoxicillin released in vitro from an oral sustained release 
tablet SR(B) 
Time  Drug released`  Amount!'  Dose' 
010  (%)  (mg)  (mg) 
0  0  0  315 
1  42  315  142.5 
2  61  457.5  52.5 
3  68  510  40 
4  74  550  51.25 
5  51.25 
6  87  652.5  32.5 
7  32.5 
8  100  750  32.5 
a Average percentage release of drug from six replication. 
b Amount of amoxicillin = 750 x average percentage release of drug. 
Drug taken as a suspension form (5 mg/ml) every hour to provide oral input equal 
to the amount released by a sustained release tablet. 44 
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Figure 3.7	  Comparison of urinary excretion rates of amoxicillin from SR(B) and 
intermittent dosing of suspension. 45 
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Figure 3.8	  Comparison of amoxicillin excreted in urine from single dose 
suspension, intermittent dosing of suspension, and capsules. 46 
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Figure 3.9	  Comparison of the urinary excretion rates of amoxicillin from single 
dose suspension, intermittent dosing of suspension, and capsules. 47 
and commercially available suspension but dosed intermittently are approximately the 
same. The difference among the bioavailabilities are within 15%. 
In order to make a sustained release dosage form for a drug which has an 
absorption window, it is necessary to find a way to retain the drug at or above the 
absorption window. Although amoxicillin is reported to be acid stable, the stability is 
maximum at pH 4.8. The drug degrades in gastric fluid (pH=1.4 + 0.1). Figure 
2.10 shows that the concentration of amoxicillin decreases over time in gastric fluid. 
The degradation half-life is 8.08 hours. Thus, if a controlled release dosage form 
containing amoxicillin is designed to remain in the stomach over 12 hours, up to 
about 65% of the drug may degrade. This information in conjunction with the 
presence of an absorption window suggests that it will be very difficult to develop a 
fully bioavailable oral controlled release dosage form for amoxicillin. 48 
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Figure 3.10	  Stability of amoxicillin in gastric fluid (pH = 1.4 ± 0.1) at room 
temperature during a 24 hour period. 49 
CONCLUSION 
A sustained release formulation of amoxicillin has been formulated and tested. 
The desired release rate in vitro was achieved but the bioavailability is rather low due 
to an absorption window. The results suggest that a fully bioavailable oral controlled 
release dosage form of amoxicillin is not possible unless a way to found to protect the 
drug from gastric degradation and to retain the dosage form in the upper small 
intestine (in the area of the absorption widow). 50 
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PROFILES OF AMOXICILLIN EXCRETED IN URINE
 
AND THE EXCRETION RATE
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Figure A.1  Profiles of amoxicillin excreted in urine (solid circle) and the excretion 
rate (triangle) for capsules for trial 1. 58 
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Figure A.2	  Profiles of amoxicillin excreted in urine (solid circle) and the excretion 
rate (triangle) for capsules for trial 2. 59 
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Figure A.3	  Profiles of amoxicillin excreted in urine (solid circle) and the excretion 
rate (triangle) for sustained release tablet containing 7.8% stearic acid 
for trial 1. 60 
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Figure A.4	  Profiles of amoxicillin excreted in urine (solid circle) and the excretion 
rate (triangle) for sustained release tablet containing 7.8% stearic acid 
for trial 2. 61 
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Figure A.5	  Profiles of amoxicillin excreted in urine (solid circle) and the excretion 
rate (triangle) for sustained release tablet containing 14.5% stearic acid 
for trial 1. 62 
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Figure A.6	  Profiles of amoxicillin excreted in urine (solid circle) and the excretion 
rate (triangle) for sustained release tablet containing 14.5% stearic acid 
for trial 2. 63 
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Figure A.7	  Profiles of amoxicillin excreted in urine (solid circle) and the excretion 
rate (triangle) for single dosing of suspension. 64 
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Figure A.8	  Profiles of amoxicillin excreted in urine (solid circle) and the excretion 
rate (triangle) for intermittent dosing of suspension. 65 
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PREPARATION OF SOLUTIONS
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1.	  Simulated gastric fluid 
Dissolve 6.0 g of NaC1 in 21 ml concentrated HC1. Add deionized water to 3000 
ml. Adjust pH to 1.4 ± 0.1. 
2.	  Simulated intestinal fluid 
Dissolve 20.4 g of potassium phosphate monobasic (KH2PO4) in about 2000 ml 
deionized water. Add 570 ml of 0.2 N NaOH. Mix and adjust resulting solution 
with 0.2 N NaOH to pH 7.4 ± 0.1. Add deionized water to 3000 ml. 
3.	  Solution of pH adjustment 
Add 100 ml of 0.5 M disodium hydrogen phosphate to 350 ml of deionized 
water. Adjust pH to 4.85 with 1 M citric acid. Dilute with deionized water to 500 
ml. 
4.	  HPLC mobile phase 
Add 200 ml methanol in 3800 ml 0.005 M potassium dihydrogen phosphate 
solution. Degas 20 minutes by stirring under vacuum. 